Women and Men Often Respond Differently to Cannabinoids. Hormones May Be Part of the Story. | Research

The takeaway

This 2013 narrative review reports that females often show stronger cannabinoid effects in lab animals and in some human studies, with estradiol and sex-linked endocannabinoid biology proposed as drivers, but firm human confirmation is limited.

Readers comparing cannabinoid effects across sexes, researchers planning sex-stratified studies, and anyone tracking how hormones might shape cannabis-related outcomes.

Rodents > humans
most mechanistic evidence for sex differences comes from animal models; firm human confirmation was limited in 2013

What the researchers found

Across studies, sex differences showed up in both species but with uneven strength. In human research, women were reported to have higher rates of cannabis abuse and dependence, more severe withdrawal, and higher relapse risk compared with men. Lab tasks in people suggested women were more affected by cannabinoids, sometimes showing enhanced performance and sometimes worse performance depending on the task.

In rodents, the pattern was clearer. Females were more sensitive to cannabinoid effects on pain-related tests, motor activity, and the reinforcing properties of cannabinoids. Studies of exposure during adolescence in both humans and rodents linked female adolescents to greater adverse effects than males.

The review highlights gonadal hormones as a likely source of these differences. Estradiol was identified as the main candidate influencing adult responses, through both activational effects across the cycle and possible organizational effects earlier in life. Sex-linked differences in the endocannabinoid system have been documented in rodents. Comparable evidence in humans had not been firmly established at the time of publication.

Why it matters

Sex can shape how drugs are experienced and how problems develop. By pulling together human data with mechanistic animal work, this review flags that women and men may not respond to cannabinoids the same way, and that hormonal context could matter. That has consequences for study design, interpretation of lab findings, and how dependence and withdrawal are evaluated across sexes.

The numbers in context

- Study type: narrative review spanning human observations and rodent experiments, no pooled statistics

- Proposed mechanism: estradiol highlighted as a key hormonal driver of sex differences (largely from animal data)

- Adolescence: both human and rodent studies linked female adolescents to greater adverse effects than males

- Endocannabinoid system: sex differences documented in rodents; not firmly established in humans

How the study worked

Narrative review of human and animal studies on sex differences in cannabinoid pharmacology, dependence, withdrawal, relapse, and task performance. The authors synthesize patterns across heterogeneous methods: epidemiologic observations, human laboratory tasks, and rodent experiments probing nociception, motor activity, reinforcement, and hormonal mechanisms. No systematic search strategy or pooled effect sizes were reported.

Who was studied

Review of studies on humans and rodents, Country not specified.

What this study cannot tell us

This is a narrative review without a prespecified search strategy or quality ratings. Many human findings come from cross-sectional or laboratory task studies that do not establish causation and often do not control for menstrual phase, contraceptive use, or product potency. Mechanistic conclusions rest heavily on rodent data, which may not translate to humans. The paper predates today’s product diversity and higher-potency markets, and it does not quantify effect sizes.

How to read the evidence

Rated preliminary: a narrative synthesis without systematic methods or pooled estimates. Human evidence is mixed and observational in parts, and much of the mechanistic support comes from animal studies.

When this study was published

Published in 2013. Pre-dates widespread legalization, higher-potency products, and newer human studies that more often include sex-stratified analyses and hormonal controls.

The bigger picture

Most cannabinoid research before and around 2013 rarely stratified outcomes by sex. This review pushed the field to consider that the same dose, timing, or exposure history may not translate across sexes, and that menstrual cycle phase or puberty timing could interact with cannabinoid responses. It also separates two evidence streams. Animal studies can map mechanisms and point to estradiol and sex-linked endocannabinoid signaling. Human findings suggest sex-linked differences in abuse liability, withdrawal, relapse, and task performance, but they are mixed, use different tasks, and often lack hormonal or cycle controls. The mechanistic story is stronger in rodents than in people.

Replication

Not stated in abstract.

Funding

Not reported in abstract.

Conflicts of interest

Not reported in abstract.

Questions still open

Do sex differences in cannabis dependence, withdrawal, and relapse persist after controlling for patterns of use, potency, and co-occurring substance use?
How do menstrual cycle phase, estradiol levels, and hormonal contraception relate to acute and chronic cannabinoid effects in humans?
Are sex differences similar across THC-dominant, CBD-rich, and mixed-ratio products, or do they vary by cannabinoid profile?
Which endocannabinoid system markers differ by sex in humans, and do they track with clinical outcomes?
Does timing of exposure during adolescence interact with puberty and hormone milestones to shape later responses?

Common questions

Are women more sensitive to cannabinoids than men?

Several human studies report that women are more affected on certain tasks and are linked to higher rates of abuse, withdrawal, and relapse. Findings are not uniform across tasks, and many studies did not control for hormonal state or product differences.

What role does estradiol play?

Animal studies suggest estradiol modulates cannabinoid effects through activational and possibly organizational mechanisms. Human evidence for direct estradiol modulation was limited at the time of this review.

Do sex differences show up in pain or reinforcement?

In rodents, yes. Females showed greater sensitivity on nociception tests and reinforcing efficacy of cannabinoids. Whether the same magnitude and directions hold in humans is not firmly established.

Are adolescent females at special risk?

Studies in both humans and rodents linked female adolescents to more adverse outcomes after cannabinoid exposure compared with males. These are associations rather than proof of causation.

Read the original research

Sex differences in cannabinoid pharmacology: A reflection of differences in the endocannabinoid system?

Life Sciences, 92(8-9), 476-481

Life Sciences is a reputable journal that publishes research in the field of pharmacology and life sciences.

View on PubMed ↗Publisher’s paper ↗

Citation

Craft, Rebecca M.; Marusich, Julie A.; Wiley, Jenny L.. (2013). Sex differences in cannabinoid pharmacology: A reflection of differences in the endocannabinoid system?. Life Sciences, 92(8-9), 476-481. https://doi.org/10.1016/j.lfs.2012.06.009